Director of Olignucleotide Chemistry and Delivery

Are you a proactive positive team player with a flexible mindset, who communicates easily with many different people, and has a passion for contributing to the development of medicines for rare CNS disorders?

Then this might be the perfect job for you!

Vico Therapeutics B.V. is a global Leiden-based biotech company with a focus on developing innovative antisense oligonucleotide therapies for rare neurological disorders (www.vicotx.com).

Preferred profile:

  • A PhD in synthetic organic chemistry (mandatory)
  • Understanding of the IP and regulatory landscape around oligonucleotide therapeutics (mandatory)
  • A proven track record of leading innovative oligonucleotide discovery and/or oligonucleotide delivery projects (mandatory)
  • 10+ years of experience in industry and oligonucleotide drug product development. Experience with conjugation chemistry is a big plus!
  • Deep understanding of modern methods in synthetic chemistry with an emphasis on nucleosides, nucleotides and oligonucleotide synthesis, and oligonucleotide conjugation chemistries
  • Strong track record of publications and/or patent applications in your area of expertise
  • Highly proficient in both spoken and written English
  • Excellent interpersonal communication and leadership skills
  • Excellent at complex project management
  • Inspiring and motivating for teams that deal with a high sense of adaptability in an up-scale work environment

Key responsibilities:

  • Provide scientific direction, strategy and leadership for novel oligonucleotide chemistry, discovery and formulation as a core component of Vico’s discovery platform
  • Identify new strategies or technologies, for pursuing novel targeting, synthesis and/or delivery of oligonucleotides
  • Develop and contribute to Vico’s intellectual property portfolio
  • Directly supervise and manage Vico’s chemistry group, providing opportunities, visibility, and challenge to develop all group members
  • Oversee management of priorities, timelines, resourcing, and budget planning
  • Provide meaningful contributions to the development of organizational culture and capabilities

What do we offer?

  • Competitive salary
  • Performance bonusGood pension scheme
  • Travel allowance and work-from-home allowance
  • Several social activities and drinks

We offer you the opportunity to contribute to the development of medicines for rare CNS disorders.

Our growing team is committed to bringing new therapeutics to those patients who need it most.

The company atmosphere is very pleasant and informal, contributing to a particularly friendly working environment.

Does this description sounds appealing to you? You can mail your resume and motivation letter to Yessica.debrouwer@vicotx.com

We look forward to receiving your application!

Scroll to Top
Leadership
Leadership micah mackison

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.